Total Payments
$39,876
2018 Payments
$36,942
Companies
3
Transactions
25
Payment Breakdown by Category
Research$36,942 (92.6%)
Travel$1,980 (5.0%)
Food & Beverage$954.82 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $36,942 | 3 | 92.6% |
| Travel and Lodging | $1,980 | 8 | 5.0% |
| Food and Beverage | $954.82 | 14 | 2.4% |
Payments by Type
Research
$36,942
3 transactions
General
$2,935
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $36,942 | 3 | $0 (2018) |
| Eisai Inc. | $1,618 | 14 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $1,317 | 8 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2018 | $36,942 | 3 | Eli Lilly and Company ($36,942) |
| 2017 | $2,935 | 22 | Eisai Inc. ($1,618) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/06/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $35,659.00 | Research |
| Study: A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | ||||||
| 01/24/2018 | Eli Lilly and Company | — | — | In-kind items and services | $1,030.20 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 01/04/2018 | Eli Lilly and Company | — | — | In-kind items and services | $252.40 | Research |
| Study: A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | ||||||
| 11/17/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $102.52 | General |
| 11/16/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Travel and Lodging | In-kind items and services | $465.92 | General |
| 11/16/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $124.67 | General |
| 11/16/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $114.99 | General |
| 11/16/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Travel and Lodging | In-kind items and services | $33.00 | General |
| 11/16/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Travel and Lodging | Cash or cash equivalent | $19.08 | General |
| 11/15/2017 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $337.00 | General |
| 11/15/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $119.71 | General |
| 09/12/2017 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $672.75 | General |
| 09/12/2017 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $289.40 | General |
| 09/12/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $167.01 | General |
| 09/12/2017 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $133.50 | General |
| 09/12/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $54.74 | General |
| 09/12/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $54.74 | General |
| 09/12/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $51.35 | General |
| 09/12/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $51.35 | General |
| 09/12/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $41.35 | General |
| 09/12/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $32.84 | General |
| 09/12/2017 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $29.10 | General |
| 09/12/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $13.68 | General |
| 09/12/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $13.04 | General |
| 09/12/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $12.83 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $35,911 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,030 | 1 |
About Scott Franczek, M.D., PHD
Scott Franczek, M.D., PHD is a Neurology healthcare provider based in Wpb, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1699776161.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Scott Franczek, M.D., PHD has received a total of $39,876 in payments from pharmaceutical and medical device companies, with $36,942 received in 2018. These payments were reported across 25 transactions from 3 companies. The most common payment nature is "" ($36,942).
Ad
Practice Information
- Specialty Neurology
- Location Wpb, FL
- Active Since 08/09/2005
- Last Updated 01/05/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1699776161
Products in Payments
- CNP520 (Drug) $979.89
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.